{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:18:48Z","timestamp":1759580328545},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:00:00Z","timestamp":1397001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0094717","type":"journal-article","created":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T21:14:32Z","timestamp":1397078072000},"page":"e94717","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice"],"prefix":"10.1371","volume":"9","author":[{"given":"Johanna M.","family":"Duyvestyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha A.","family":"Dagger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Orandle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert C.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine B. F.","family":"Thien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wallace Y.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,4,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbamcr.2012.10.010","article-title":"Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases","volume":"1833","author":"B Mohapatra","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-10-0610","article-title":"Cbl and human myeloid neoplasms: the Cbl oncogene comes of age","volume":"70","author":"SC Kales","year":"2010","journal-title":"Cancer Research"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missence substitutions of c-Cbl in myeloid malignancies","volume":"68","author":"AJ Dunbar","year":"2008","journal-title":"Cancer Research"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of E3 ubiquitin ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"H Makishima","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent Cbl mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"F Grand","year":"2009","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"ML Loh","year":"2009","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","article-title":"Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia","volume":"115","author":"H Muramatsu","year":"2010","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"A Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"M Sanada","year":"2009","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2012.065375","article-title":"Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative\/myelodysplastic disorders: an analysis of 636 cases","volume":"97","author":"S Schnittger","year":"2012","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2010.09.008","article-title":"Myeloid Leukemia Development in c-Cbl RING Finger Mutant Mice is Dependent on FLT3 Signaling","volume":"18","author":"C Rathinam","year":"2010","journal-title":"Cancer Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.286.5438.309","article-title":"The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase","volume":"286","author":"CAP Joazeiro","year":"1999","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1097-2765(00)80231-2","article-title":"Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl\/Sli-1","volume":"4","author":"G Levkowitz","year":"1999","journal-title":"Molecular Cell"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1097-2765(01)00183-6","article-title":"Ring finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation","volume":"7","author":"CBF Thien","year":"2001","journal-title":"Molecular Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1182\/blood-2012-06-436675","article-title":"Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling","volume":"120","author":"SJ Taylor","year":"2012","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"A Kamath","year":"2008","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"ref17","first-page":"473","article-title":"Dasatinib (BMS-354825), a Dual SRC\/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies Cancer Research","volume":"66","author":"MM Schittenhelm","year":"2006"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/leu.2012.7","article-title":"CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors","volume":"26","author":"H Makishima","year":"2012","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-12-3425","article-title":"Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia","volume":"73","author":"S Bunda","year":"2013","journal-title":"Cancer Research"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"27450","DOI":"10.1074\/jbc.272.43.27450","article-title":"Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells","volume":"272","author":"D Linnekin","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1093\/emboj\/17.21.6250","article-title":"Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation","volume":"17","author":"I Timokhina","year":"1998","journal-title":"Embo J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/sj.onc.1202929","article-title":"Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor\/c-kit mediated activation of the Ras\/MAP kinase pathway and c-fos induction","volume":"18","author":"J Lennartsson","year":"1999","journal-title":"Oncogene"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V98.2.343","article-title":"Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells","volume":"98","author":"B O\u2019Laughlin-Bunner","year":"2001","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.exphem.2005.01.004","article-title":"Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations","volume":"33","author":"LJ Robinson","year":"2005","journal-title":"Experimental Hematology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/sj.emboj.7600841","article-title":"Loss of c-Cbl RING finger function results in high-intensity signaling and thymic deletion","volume":"24","author":"CBF Thien","year":"2005","journal-title":"Embo J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"K Porkka","year":"2008","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/onc.2010.430","article-title":"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab","volume":"30","author":"EF Dunn","year":"2011","journal-title":"Oncogene"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2007-10-116590","article-title":"Validation of PDGFRbeta and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib","volume":"112","author":"AM Coluccia","year":"2008","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/ijc.24606","article-title":"Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model","volume":"125","author":"R Vitali","year":"2009","journal-title":"Int J Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1158\/1078-0432.CCR-11-3359","article-title":"Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis","volume":"18","author":"CM Chan","year":"2012","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"M Ogawa","year":"1991","journal-title":"The Journal of experimental medicine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature11885","article-title":"Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches","volume":"495","author":"L Ding","year":"2013","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2656","article-title":"The follicular versus marginal zone B lymphocyte cell fate decision","volume":"9","author":"S Pillai","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1038\/sj.onc.1208075","article-title":"Src-family kinases in B-cell development and signaling","volume":"23","author":"SB Gauld","year":"2004","journal-title":"Oncogene"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.4049\/jimmunol.1200649","article-title":"Lyn signaling to upregulate GANP is critical for the survival of high-affinity B cells in germinal centers of lymphoid organs","volume":"189","author":"K Kuwahara","year":"2012","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"ML Hibbs","year":"1995","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/1074-7613(95)90126-4","article-title":"Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice","volume":"3","author":"H Nishizumi","year":"1995","journal-title":"Immunity"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1101\/gad.1651408","article-title":"The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells","volume":"22","author":"C Rathinam","year":"2008","journal-title":"Genes and Development"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"M Levis","year":"2011","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2012.05.003","article-title":"Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A","volume":"95","author":"JL Dargart","year":"2012","journal-title":"Antiviral Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.2010.08507.x","article-title":"Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals","volume":"153","author":"AM McCaig","year":"2011","journal-title":"British journal of haematology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"PC Amrein","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0094717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T07:52:34Z","timestamp":1540021954000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0094717"}},"subtitle":[],"editor":[{"given":"Connie J.","family":"Eaves","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,9]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0094717","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,9]]}}}